These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9200390)

  • 21. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators.
    Barbagelata A; Califf RM; Sgarbossa EB; Goodman SG; Stebbins AL; Granger CB; Suarez LD; Borruel M; Gates K; Starr S; Wagner GS
    J Am Coll Cardiol; 1997 Mar; 29(4):770-7. PubMed ID: 9091523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
    Granger CB; Becker R; Tracy RP; Califf RM; Topol EJ; Pieper KS; Ross AM; Roth S; Lambrew C; Bovill EG
    J Am Coll Cardiol; 1998 Mar; 31(3):497-505. PubMed ID: 9502626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
    Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ
    Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-benefit of thrombolysis.
    Simoons ML
    Cardiol Clin; 1995 Aug; 13(3):339-45. PubMed ID: 7585771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
    Al-Khatib SM; Stebbins AL; Califf RM; Lee KL; Granger CB; White HD; Armstrong PW; Topol EJ; Ohman EM;
    Am Heart J; 2003 Mar; 145(3):515-21. PubMed ID: 12660676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
    J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
    Smith BJ
    J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators.
    Lee KL; Woodlief LH; Topol EJ; Weaver WD; Betriu A; Col J; Simoons M; Aylward P; Van de Werf F; Califf RM
    Circulation; 1995 Mar; 91(6):1659-68. PubMed ID: 7882472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
    Gillis JC; Wagstaff AJ; Goa KL
    Drugs; 1995 Jul; 50(1):102-36. PubMed ID: 7588083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TIMI grade flow, mortality, and the GUSTO-III trial.
    Stringer KA
    Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. tPA fast by GUSTO.
    Horton R
    Lancet; 1993 May; 341(8854):1188. PubMed ID: 8098084
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data.
    Wilcox RG
    Am J Cardiol; 1996 Dec; 78(12A):20-3. PubMed ID: 8990407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
    Barbagelata NA; Granger CB; Oqueli E; Suárez LD; Borruel M; Topol EJ; Califf RM
    Am Heart J; 1997 Mar; 133(3):273-82. PubMed ID: 9060794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fibrinolysis in pulmonary embolism].
    Thabut G; Jebrak G
    Presse Med; 2001 Oct; 30(30):1501-6. PubMed ID: 11712211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.
    Califf RM; Pieper KS; Lee KL; Van De Werf F; Simes RJ; Armstrong PW; Topol EJ
    Circulation; 2000 May; 101(19):2231-8. PubMed ID: 10811588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
    Peuhkurinen K; Risteli L; Jounela A; Risteli J
    Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
    Heyland DK; Gafni A; Levine MA
    J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.